Immunological response after early extra and regular MMR immunization; 6 years follow-up
Completed
- Conditions
- Measles infectionparamyxovirus10047438
- Registration Number
- NL-OMON48447
- Lead Sponsor
- RIVM
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 90
Inclusion Criteria
•Previous participation in the study on the immunological effects of early measles vaccination, as described in a separate study protocol (NL45616.094.13/IIV-273)
•The parents/legally representatives accept participation in the trial according to the described procedures
•Presence of a signed informed consent
•Children must have received their NIP vaccinations according to schedule.
Exclusion Criteria
•Receiving immunosuppressive medication
•Presence of a serious disease that requires medical care that can interfere with the results of the study
•Known or suspected immunological disorder
•Bleeding disorders
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>• Measles specific serum neutralizing antibodies 6 years after MMR-1 at 14<br /><br>months of age </p><br>
- Secondary Outcome Measures
Name Time Method <p>• Measles specific serum IgG antibody and avidity (Luminex), and functional<br /><br>antibody characteristics prior 6 years after MMR-1 at 14 months of age<br /><br>• Serum IgG antibody concentrations against mumps and rubella (Luminex) 6 years<br /><br>after MMR-1 at 14 months of age<br /><br>• Antibodies against other NIP vaccines 6 years after MMR-1 at 14 months of age </p><br>